Interleukin-2 fusion toxin: Targeted therapy for cutaneous T cell lymphoma

Annals of the New York Academy of Sciences

Volumn 941, Issue , 2001, Pages 166-176

  Foss, Francine M ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Diphtheria toxin; Interleukin 2 fusion toxins; T cell directed therapies

Indexed keywords

DAB 389 INTERLEUKIN 2; DAB 486 INTERLEUKIN 2; INTERLEUKIN 2 FUSION TOXIN; INTERLEUKIN 2 RECEPTOR; TOXIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION FUNCTION; DRUG MECHANISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MODULATION; MULTICENTER STUDY; PROTEIN EXPRESSION; SKIN LYMPHOMA; T CELL LYMPHOMA; TREATMENT OUTCOME;

EID: 0034808904     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03720.x     Document Type: Conference Paper

References (43)

1. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity
2. Structure function analyses of diphtheria toxin by use of monoclonal antibodies
3. Inhibition of coated pit formation in Hep2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin
4. Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: Electron microscopic evaluation
5. +-ATPase in regulating ATP-dependent endosome acidification
6. Diphtheria toxin fragment forms large pores in phospholipid bilayer membranes
7. Diphtheria toxin forms transmembrane channels in planar lipid bilayers
8. Diphtheria-toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein
9. Interleukin-2 targeted cytotoxicity: Selective action of a diphtheria toxin-related interleukin-2 fusion toxin
10. Sequential effects of interleukin-2 diphtheria toxin fusion protein on T-cell activation
11. Protein engineering of diphtheria toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high affinity IL-2 receptor bearing target cells
12. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor
13. Demonstration of a non-TAC peptide that binds interleukin 2: A potential participant in a multichain interleukin-2 receptor complex
14. Cloning of the γ chain of the human IL-2 receptor
15. The multichain interleukin-2 receptor. A target for immunotherapy in lymphoma, autoimmune disorders, and organ allografts
16. Two-dimensional analysis of interleukin 2-regulated tyrosine kinase activation mediated by p75 β subunit of the interleukin-2 receptor
17. Protein tyrosine phosphorylation associated with activation of the interleukin-2 receptor
18. Sharing of the interleukin-2 receptor γ chain between receptors for IL-2 and IL-4
19. Functional participation of the IL-2 Rγ chain in IL-7 receptor complexes
20. Utilization of the β and γ chains of the IL-2 R by the novel cytokine IL-15
21. The structure, function, and expression of interleukin-2 receptors on normal and malignant T cells
22. IL-2 receptor expression in human lymphoid lesions
23. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistochemical study of 300 cases
24. The interleukin-2 receptor and its expression in the acute leukemias and lymphoproliferative disorders
25. Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies
26. Cutaneous T-cell lymphoma: Immunocytochemical study on activation/proliferation and differentiation associated antigens in lymph nodes, skin, and peripheral blood
27. Detection of the alpha and beta components of the interleukin-2 receptor using immunologic techniques
28. Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells
29. 486IL-2) in hematologic malignancies expressing the IL-2 receptor
30. 486IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy
31. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T cell lymphoma
32. 486IL-2 in hematologic cancers
33. 486IL-2: Efficacy in mycosis fungoides and other non-Hodgkin's lymphomas
34. 486IL-2 in refractory mycosis fungoides and the Sézary syndrome: Correlation of activity and IL-2 receptor expression in a phase II study
35. 389IL-2) in lymphomas expressing the receptor for interleukin-2
36. 389IL-2 fusion toxin in mycosis fungoides
37. 389IL-2 (ONTAK) fusion protein
38. 389IL2 (Ontak) for the treatment of cutaneous T-cell lymphoma
39. 389IL-2 in non-Hodgkin's lymphoma: Decreased frequency and severity with steroid premedication
40. 389IL-2
41. Signaling from the IL-2 receptor to the nucleus
42. Retinoid regulation of interleukin-2 receptors on human T-cells
43. Enhanced cytotoxicity to DAB389IL-2 (ONTAK) in human T-cell lines by retinoic acid